Triple
T7110923
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Orphan Drug Act of 1983 |
E165703
|
entity |
| Predicate | relatedTo |
P37
|
FINISHED |
| Object | European Union orphan medicinal product regulation |
E546469
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: European Union orphan medicinal product regulation | Statement: [Orphan Drug Act of 1983, relatedTo, European Union orphan medicinal product regulation]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: European Union orphan medicinal product regulation Context triple: [Orphan Drug Act of 1983, relatedTo, European Union orphan medicinal product regulation]
-
A.
Regulation (EC) No 141/2000 on orphan medicinal products
chosen
Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
-
B.
European Union pharmaceutical legislation
European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
-
C.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
-
D.
European medicines regulatory authorities
European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
-
E.
European Union medical device regulations
European Union medical device regulations are a comprehensive set of legal and technical requirements governing the safety, performance, quality management, and market approval of medical devices within EU member states.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c6888120f081908f8f01b201dc4a4c |
completed | March 27, 2026, 1:39 p.m. |
| NER | Named-entity recognition | batch_69c6e5ecd4488190bf19e42de55da98b |
completed | March 27, 2026, 8:17 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c79cb8d4988190945516cee5d6d53b |
completed | March 28, 2026, 9:17 a.m. |
Created at: March 27, 2026, 2:43 p.m.